ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Quantitative Mass Spectrometry-Based Biodistribution of Monoclonal Antibodies: An Alternative to Radio-Biodistribution.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies (mAbs) are excellent tools for generating targeted therapies for cancer treatment, and an early assessment of their biodistribution properties is essential in the discovery process. Traditionally, radiolabeling methods are widely used, but they require structural alterations of the antibody, radiation exposure, and specialized infrastructure. In this work, we present the implementation of a non-radioactive Mass Spectrometry (MS)-based method to assess the ex vivo quantitative biodistribution of tumor-targeting mAbs directed against the tumor extracellular matrix. By combining protein A purification with a stable isotopically labeled standard, we obtained a versatile method that can be easily transferred to different analytes. The methodology was orthogonally validated by direct comparison against radiolabel-based biodistribution studies, demonstrating high reliability and accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.